Journal Basic Info

  • Impact Factor: 2.709**
  • H-Index: 11 
  • ISSN: 2474-1663
  • DOI: 10.25107/2474-1663
**Impact Factor calculated based on Google Scholar Citations. Please contact us for any more details.

Major Scope

  •  Radiation Oncology
  •  Prostate Cancer
  •  Urological Cancers
  •  Pancreatic Cancer
  •  Paediatric Cancers
  •  Ovarian Cancer
  •  Head and Neck Oncology
  •  Thoracic Oncology


Citation: Clin Oncol. 2022;7(1):1929.DOI: 10.25107/2474-1663.1929

Effectivity of Long Antigen Exposition Dendritic Cell Therapy (LANEX-DC®) in the Adjuvant Treatment of Gastric Cancer

Frank Gansauge and Bertram Poch

Center for Oncologic, Endocrine and Minimal-Invasive Surgery, Germany
LDG - Laboratories Dr. Gansauge - GmbH, Germany

*Correspondance to: Frank Gansauge 

 PDF  Full Text Research Article | Open Access


Introduction: Even after surgical resection and multimodal treatment in gastric cancer the 5-year Disease Free Survival times (DFS) as well as Overall Survival rates (OS) are still below one third of the patients. Here we retrospectively analyzed the outcome of immunotherapy in the additional adjuvant treatment of gastric cancer with Long Antigen Exposition Dendritic Cell therapy (LANEXDC ®) in 16 patients who were treated at our institution (intent-to- treat-analysis).
Patients: Data were available of 16 patients. Dendritic Cells (LAEX-DC®) were produced according to a recently published protocol.
Results: Therapy was well tolerated and no serious side effects were observed. Five year DFS and OS were 62.5% and 67.5%. Interestingly, two of the patients developed recurrence of the disease more than 7 years following resection for gastric cancer.
Conclusion: We were able to show in a small cohort of patients that additional treatment with dendritic cells (LANEX-DC®) is highly effective and extends the DFS and OS in the adjuvant treatment of gastric cancer.


Gastric cancer; Dendritic cells; LANEX-DC®; Immunotherapy; Adjuvant

Cite the Article:

Gansauge F, Poch B. Effectivity of Long Antigen Exposition Dendritic Cell Therapy (LANEX-DC®) in the Adjuvant Treatment of Gastric Cancer. Clin Oncol. 2022;7:1929..

Search Our Journal

Journal Indexed In

Articles in PubMed

LINGO-1 is a New Therapy Target and Biomarker for Ewing Sarcoma
 PubMed  PMC  PDF  Full Text
NMR Metabolomics in Ionizing Radiation
 PubMed  PMC  PDF  Full Text
View More...

Articles with Grants

Pediatric Cancer Predisposition Documentation Tool - Standardized Reporting Form for Children and Adolescents with Suspected Cancer Predisposition Syndrome
 Abstract  PDF  Full Text
Treatment of Breast Cancer by Internal and External Chinese Medicine Combination Therapy: An Effective Case Report of Traditional Chinese Medicine Treatment
 Abstract  PDF  Full Text
View More...